GSK obtains FDA OK for new presentation of Menveo
GSK's Menveo one-vial presentation, which is used to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W, will initially be available to U.S. federal customers, with broader availability anticipated in mid-2023.